Preferred Label : Autologous PBMC-derived Engineered Leukocyte Immunostimulatory Cells-activated Effector
Cells;
NCIt synonyms : SUPLEXA Therapeutic Cells; Autologous PBMC-derived ENLIST Cells-activated Effector Cells;
NCIt definition : A preparation of cytotoxic, autologous effector cells specifically targeted towards
tumor cells and comprised primarily of natural killer (NK) cells, CD56 NK T-cells
(NKTs), CD8 T-cells and gamma delta T-cells stored in cryogenic media, with potential
immunomodulating and antineoplastic activities. The autologous effector cells are
prepared by collecting peripheral blood mononuclear cells (PBMCs) from cancer patients,
which are stimulated with the induction reagent engineered leukocyte immunostimulatory
(ENLIST) cells to activate and differentiate the PBMCs; the activated cells are expanded
with cytokines, and the tumor killing effector cells, including NK cells, CD8 T-cells,
TCRgd T-cells, NKT cells and some CD4 T-cells, are cryopreserved. Upon intravenous
re-administration into the patient, the autologous PBMC-derived ENLIST cells-activated
effector cells recognize and induce an immune-mediated killing of tumor cells. ENLIST
cells are engineered SK-MEL2 melanoma cell lines (APX-DC and APX-L) that express immunomodulatory
proteins that are engineered for membrane expression and contain endogenous tumor-associated
antigens (TAAs).;
Drug name : Suplexa;
NCI Metathesaurus CUI : CL1779203;
Origin ID : C187047;
UMLS CUI : C5670964;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
